
From: King Kimchi <consulting012345@gmail.com>
Sent: Mon 10/5/2020 8:36:14 PM (UTC)
To: compliance <compliance@Safechain.com>, Charles Boyd <CharlesB@Safechain.com>, Abbie Divilio <AbbieD@Safechain.com>
Attachment: CDGXKA.pdf

Please let me know if it's all good to go

GOVERNMENT
EXHIBIT

310

1:24-cr-20255-WPD

SAFE CHAIN SOLUTIONS, LLC

Drug Supply Chain Security Act Document**(TI) Transaction Information**

Drug Name, Strength, Dosage Form, Container Size: BIKTARVY 30CT			Reference Number: <u>INV 6901</u>
NDC: 61958-2501-01			Document Type: <u>INVOICE</u>
Lot Number <u>CDGXKA</u> Quantity <u>5</u> Unique Serial #			Reference Date: <u>09/28/2020</u>

(TH) Transaction History

Manufacturer's Name: Gilead Sciences, Inc.
 Manufacturer's information: 33 Lakeside Drive, Foster City, CA 94404

SOLD TO: Name: Rochester Drug Co-Op Inc Address: 116 Lehigh Dr #3013 Fairfield, NJ 07004 Date Purchased & Ref : 09/04/18 PO#R2367	SHIPPED TO: Name: Rochester Drug Co-Op Inc Address: 116 Lehigh Dr #3013 Fairfield, NJ 07004 Date Received & Ref : 09/04/18
SOLD TO: Name: Instacare Pharmacy DBA Brookville RX Address: 235-20 147th Ave Rosedale, NY 11422 Date Purchased & Ref : 10/15/18 PO#001IC545	SHIPPED TO: Name: Instacare Pharmacy DBA Brookville RX Address: 235-20 147th Ave Rosedale, NY 11422 Date Received & Ref : 10/15/18
SOLD TO: Name: BOULEVARD 9229 LLC Address: 9229 QUEENS BLVD STE 11 REGO PARK, NY 11374 Date Purchased & Ref : 09/15/20 PO#01209744	SHIPPED TO: Name: BOULEVARD 9229 LLC Address: 9229 QUEENS BLVD STE 11 REGO PARK, NY 11374 Date Received & Ref : 09/15/20
SOLD TO: Name: SAFE CHAIN SOLUTIONS, LLC Address: 822 CHESAPEAKE DR CAMBRIDGE MD 21613 Date Purchased & Ref : 09/28/20 PO#9311	SHIPPED TO: Name: SAFE CHAIN SOLUTIONS, LLC Address: 822 CHESAPEAKE DR CAMBRIDGE MD 21613 Date Received & Ref : 09/28/20
SOLD TO: Name: Address: Date Purchased & Ref :	SHIPPED TO: Name: Address: Date Received & Ref :

(TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.